Profiling of 179 miRNA Expression in Blood Plasma of Lung Cancer Patients and Cancer-Free Individuals.

Autor:	Zaporozhchenko IA; Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia. ivanzap@niboch.nsc.ru.; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia. ivanzap@niboch.nsc.ru., Morozkin ES; Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia.; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia., Ponomaryova AA; Laboratory of Molecular Oncology and Immunology, RAMS Tomsk Cancer Research Institute, Tomsk, Russia.; Department of Applied Physics, National Research Tomsk Polytechnic University, Tomsk, Russia., Rykova EY; Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia.; Department of engineering problems in ecology, Novosibirsk State Technical University, Novosibirsk, Russia., Cherdyntseva NV; Laboratory of Molecular Oncology and Immunology, RAMS Tomsk Cancer Research Institute, Tomsk, Russia.; Laboratory for Translational Cell and Molecular Biomedicine, National Research Tomsk State University, Tomsk, Russia., Zheravin AA; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia., Pashkovskaya OA; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia., Pokushalov EA; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia., Vlassov VV; Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia., Laktionov PP; Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia.; Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, Russia.
Jazyk:	angličtina
Zdroj:	Scientific reports [Sci Rep] 2018 Apr 20; Vol. 8 (1), pp. 6348. Date of Electronic Publication: 2018 Apr 20.
DOI:	10.1038/s41598-018-24769-2
Abstrakt:	Lung cancer is one of major cancers, and survival of lung cancer patients is dictated by the timely detection and diagnosis. Cell-free circulating miRNAs were proposed as candidate biomarkers for lung cancer. These RNAs are frequently deregulated in lung cancer and can persist in bodily fluids for extended periods of time, shielded from degradation by membrane vesicles and biopolymer complexes. To date, several groups reported the presence of lung tumour-specific subsets of miRNAs in blood. Here we describe the profiling of blood plasma miRNAs in lung cancer patients, healthy individuals and endobronchitis patients using miRCURY LNA miRNA qPCR Serum/Plasma Panel (Exiqon). From 241 ratios differently expressed between cancer patients and healthy individuals 19 miRNAs were selected for verification using the same platform. LASSO-penalized logistic regression model, including 10 miRNA ratios comprised of 14 individual miRNAs discriminated lung cancer patients from both control groups with AUC of 0.979.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu